Background: Reported relapse and recurrence rates in bipolar disorder (BD) differ significantly between studies. Most data originate from highly selective patients participating in sponsored randomized controlled trials with narrow inclusion criteria. To estimate the true risk of a subsequent mood episode (SME) under real-world conditions, we conducted a meta-analysis of rates of SME as reported in naturalistic BD studies. Methods: PubMed, ScienceDirect, Scopus, and Web of Knowledge were searched until July 2015. Studies reporting the time until the emergence of an SME, from which individual data or Kaplan-Meier plots with censors marked could be retrieved, were included. Results: Twelve studies comprising 5,837 patients met the inclusion criteria. The median time to an SME in adults after an index episode was 1.44 years. The risk of an SME was 44% during the first year. Not having a SME during this first year lowered this risk to 19% in the second year. The risk was higher in bipolar II disorder (BD-II) than in bipolar I disorder (BD-I; HR = 1.5). In BD-I, the risk of a subsequent manic, mixed, or depressive mood episode was higher after an index episode of the same polarity (HR = 1.89-5.14). The overall risk of an SME was higher in patients with persisting subsyndromal symptoms (HR = 2.17). Conclusions: The data from this study provide a more reliable estimate of the risk of an SME in BD in real-world settings. Further research into the longitudinal course of BD-II is warranted to confirm its role as a risk factor for SME.

Keywords:
Recurrence, Relapse, Bipolar disorder, Meta-analysis
1.
Zimmerman M: Screening for bipolar disorder: confusion between case-finding and screening. Psychother Psychosom 2014;83:259-262.
2.
Goodwin FK, Jamison KR: Manic-Depressive Illness, ed 2. New York, Oxford University Press, 2007.
3.
Post RM, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA: Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010;71:1176-1186.
4.
Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, Solomon DA: Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008;65:386-394.
5.
Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217-224.
6.
Strober M, Schmidt-Lackner S, Freeman R, Bower S, Lampert C, DeAntonio M: Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up. J Am Acad Child Adolesc Psychiatry 1995;34:724-731.
7.
Dittmann S, Biedermann NC, Grunze H, Hummel B, Schärer L, Kleindienst N, Forsthoff A, Matzner N, Walser S, Walden J: The Stanley Foundation Bipolar Network: results of the naturalistic follow-up study (NFS) after 2.5 years of follow-up in the German centres. Neuropsychobiology 2002;46(suppl 1):2-9.
8.
Gonzalez-Pinto A, Barbeito S, Alonso M, Alberich S, Haidar MK, Vieta E, Tabares-Seisdedos R, Zorrilla I, Gonzalez-Pinto MA, Lopez P: Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain. J Clin Psychiatry 2011;72:671-676.
9.
Kulkarni J, Filia S, Berk L, Filia K, Dodd S, de CA, Brnabic AJ, Lowry AJ, Kelin K, Montgomery W, Fitzgerald PB, Berk M: Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice. BMC Psychiatry 2012;12:228.
10.
Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Astrom M, Paulsson B: Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029-1049.
11.
Simhandl C, Konig B, Amann BL: A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry 2014;75:254-262.
12.
Möller HJ: Effectiveness studies: advantages and disadvantages. Dialogues Clin Neurosci 2011;13:199-207.
13.
Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, Suppes T, Sachs GS, Chengappa KR, Grunze H, Mitchell PB, Kanba S, Berk M: The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009;11:453-473.
14.
Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E: Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012;22:339-346.
15.
Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J: Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry 2006;189:118-123.
16.
Fava GA: Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychol Med 1999;29:47-61.
17.
Post RM, Leverich GS, Kupka RW, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, Suppes T, Nolen WA: Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010;71:864-872.
18.
Radua J, Mataix-Cols D: Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br J Psychiatry 2009;195:393-402.
19.
Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom 2015;84:1-3.
22.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
23.
Tohen M, Waternaux CM, Tsuang MT: Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111.
24.
De Dios C, Ezquiaga E, Agud JL, Vieta E, Soler B, Garcia-Lopez A: Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J Affect Disord 2012;143:160-165.
25.
Montoya A, Tohen M, Vieta E, Casillas M, Chacon F, Polavieja P, Gilaberte I: Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord 2010;127:50-57.
26.
Strakowski SM, Tsai SY, DelBello MP, Chen CC, Fleck DE, Adler CM, Arndt S, Amicone J: Outcome following a first manic episode: cross-national US and Taiwan comparison. Bipolar Disord 2007;9:820-827.
27.
Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E: Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord 2007;9:45-52.
28.
Tundo A, Calabrese JR, Marchetti F, Dell'Osso L, Proietti L, De Filippis R: Continuous circular cycling in bipolar disorder as a predictor of poor outcome. J Affect Disord 2013;150:823-828.
29.
Geller B, Tillman R, Bolhofner K, Zimerman B: Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. Arch Gen Psychiatry 2008;65:1125-1133.
30.
Kraemer S, Minarzyk A, Eppendorfer S, Henneges C, Hundemer HP, Wilhelm S, Grunze H: Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study. BMC Psychiatry 2013;13:193.
31.
Frecska E, Kovacs AI, Balla P, Falussy L, Ferencz A, Varga Z: The message of the survival curves. 1. Composite analysis of long-term treatment studies in bipolar disorder. Neuropsychopharmacol Hung 2012;14:155-164.
32.
Gitlin MJ, Swendsen J, Heller TL, Hammen C: Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640.
33.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661.
34.
Angst J, Gamma A, Sellaro R, Lavori PW, Zhang H: Recurrence of bipolar disorders and major depression: a life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003;253:236-240.
35.
Mantere O, Suominen K, Valtonen HM, Arvilommi P, Leppamaki S, Melartin T, Isometsa E: Differences in outcome of DSM-IV bipolar I and II disorders. Bipolar Disord 2008;10:413-425.
36.
Born C, Seitz NN, Grunze H, Vieta E, Dittmann S, Seemuller F, Amann B: Preliminary results of a fine-grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective life-chart-methodology. Acta Psychiatr Scand 2009;120:474-480.
37.
Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-269.
38.
Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, Frye MA, Keck PE Jr, McElroy SL, Grunze H, Post RM: Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-535.
39.
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB: Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322-1330.
40.
Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016;85:270-288.
41.
Offidani E, Fava GA, Tomba E, Baldessarini RJ: Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 2013;82:132-141.
42.
Sani G, Napoletano F, Vohringer PA, Sullivan M, Simonetti A, Koukopoulos A, Danese E, Girardi P, Ghaemi N: Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom 2014;83:213-221.
43.
Altshuler LL, Post RM, Black DO, Keck PE Jr, Nolen WA, Frye MA, Suppes T, Grunze H, Kupka RW, Leverich GS, McElroy SL, Walden J, Mintz J: Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry 2006;67:1551-1560.
44.
Fava GA, Bech P: The concept of euthymia. Psychother Psychosom 2016;85:1-5.
45.
Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR: Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry 2006;67:1721-1728.
46.
Isasi AG, Echeburua E, Liminana JM, Gonzalez-Pinto A: How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial. J Affect Disord 2010;126:80-87.
47.
Novo P, Landin-Romero R, Radua J, Vicens V, Fernandez I, Garcia F, Pomarol-Clotet E, McKenna PJ, Shapiro F, Amann BL: Eye movement desensitization and reprocessing therapy in subsyndromal bipolar patients with a history of traumatic events: a randomized, controlled pilot-study. Psychiatry Res 2014;219:122-128.
48.
Calabrese JR, Vieta E, El Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R: Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957-963.
49.
Grimmer Y, Hohmann S, Poustka L: Is bipolar always bipolar? Understanding the controversy on bipolar disorder in children. F1000Prime Rep 2014;6:111.
50.
Solomon DA, Leon AC, Coryell WH, Endicott J, Li C, Fiedorowicz JG, Boyken L, Keller MB: Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry 2010;67:339-347.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.